Drip Drop has named David Zezza, managing partner at Pacific Advantage Capital, as chairman of its board of directors. The firm has also added Stan Lech, president of PharmaMax, to its board. Based in San Francisco, Drip Drop is a provider of oral rehydration solutions.
SAN FRANCISCO, Dec. 11, 2013 /PRNewswire/ — Drip Drop Inc., makers of the first oral rehydration solution (ORS) to combine medical standards of rehydration therapy and excellent taste, made two important additions to its Board of Directors this month: Stan Lech, President of PharmaMax, has joined the board, and David Zezza, a Managing Partner for Pacific Advantage Capital (PAC), and one of Drip Drop’s earliest and most active investors, was elected Chairman.
“We are absolutely thrilled to be building a board of directors with this level of experience and expertise,” said Anne Kallin Zehren, Drip Drop’s CEO. “Not only are Stan and David deeply committed to our mission to change the way the world hydrates, but they will be invaluable as Drip Drop grows its footprint in both the consumer and medical space.”
Stan Lech brings 30 years of experience in consumer health and product development. During his 16-year tenure at GlaxoSmithKline, Stan lead Global R&D for the Wellness Category, oversaw new category development as Global Vice President of the Venture Group, and oversaw a portfolio of $8 billion dollars in annual sales as Global Vice President of Innovation and Worldwide Product Development. Prior to GlaxoSmithKline, Stan held previous management and scientific roles at Warner Lambert, UniLever and the Block Drug Company.
Stan has been personally involved and responsible for more than 250 new product launches in the global marketplace, including Listerine, Tums, Aquafresh, Sensodyne, Nicorette, Nicoderm, Neosporin, Abreva, Polident, Poligrip, Zovirax, Benadryl, Sudafed, Actifed, Contac, and Bactroban.
He is currently President of PharmaMax, an innovative and high quality pharmaceutical service provider with operations in New Jersey and Taizhou, China. PharmaMax is focused on novel therapies for chronic disease effecting Respiratory, Cardiovascular and Mental Health. Stan is also the President of TruEast, Inc. which provides market entry strategies into China for small and medium sized healthcare companies.
“In the world of consumer healthcare, it’s rare to come across a product like Drip Drop, which I believe will be a truly disruptive innovation in hydration therapy,” said Stan. “I joined Drip Drop because I care deeply about improving the quality of life of people around the world. I spent 29 years doing this in corporate America and now I can do it even more purposely as a Drip Drop board member.”
David Zezza is a Managing Partner for Pacific Advantage Capital (“PAC”), an Asia & US-centric investment management company focused on public and private equity investments with a focus on supporting high growth ventures, companies expanding into new markets, and special situations investments. With more than 25 years of experience in the investment and finance fields David has lived and worked in Europe and Asia for over 22 years.
David has been part of a number of boards and currently sits on the UK Board of Trustees for the Global Fund for Children. David is also on the Board of Visitors for the Sanford School of Public Policy at Duke University.
Drip Drop is an innovative rehydration solution that combines best-in-class medical technology with great taste. Developed by Eduardo Dolhun MD, a Mayo trained physician and Stanford Adjunct Assistant Clinical Professor, Drip Drop’s formula helps prevent dehydration, maintain electrolyte balance, and replenish fluids lost through illness or activity. Proven worldwide in the most challenging circumstances, Drip Drop(R) has won early adoption by a broad spectrum of users that include the Stanford University Medical Center, UCSF Medical Center, elite athletes, U.S. Special Forces, humanitarian workers, pharmacists, and patients with chronic illness.
For more information, please visit www.DripDrop.com